World’s largest independent cancer research charity.
A UK NHS study indicates focal therapy provides durable long‑term cancer control for many prostate cancer patients, with just two of 3,477 men dying from prostate cancer a decade after treatment and lower side‑effects. The government is expanding access to more centres.
The UK has passed the Tobacco and Vapes Act, which has created a rolling age ban that will permanently prevent anyone born on or after 1 January 2009 from legally buying tobacco. The law has also granted ministers broad powers to regulate vaping — including flavours, packaging, displays and where vaping is allowed — and will tighten sales rules for under‑18s.
Cancer Research UK reports over 403,000 annual cancer diagnoses in the UK, driven by an ageing population. Waiting times are high and early diagnosis has not improved, while the government’s National Cancer Plan aims to accelerate care and screening. TheIndependent notes the link between obesity and rising incidence across several cancers, including bowel cancer, with calls for stronger public health action.
A roundup of recent cancer breakthroughs highlights new immunotherapies, targeted drugs and surgical-sparing treatments. The Independent reports on Scolyer’s pioneering work and a landmark NICE decision; The Guardian covers durvalumab’s promise in bladder cancer; Business Insider UK and Reuters summarize ASCO findings on pancreatic and colon cancers, among others.
[Synopsis here]
A QMUL-led Lancet study shows the HPV vaccine has dramatically reduced cervical cancer deaths among 20-24-year-olds in England from 2020–2024. England also sees an 80% fall in deaths in 2015–2019 for this age group. Yet uptake gaps threaten future gains as vaccination rates fall in parts of the country.
AstraZeneca has announced that Wainua, its gene-silencer drug for transthyretin-mediated amyloid cardiomyopathy, did not meet its primary endpoint in a phase 3 trial. The news triggers a sharp stock drop and prompts investors to rethink the company’s long-term growth targets and the strength of its pipeline.